ATE364701T1 - Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren - Google Patents

Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren

Info

Publication number
ATE364701T1
ATE364701T1 AT96902180T AT96902180T ATE364701T1 AT E364701 T1 ATE364701 T1 AT E364701T1 AT 96902180 T AT96902180 T AT 96902180T AT 96902180 T AT96902180 T AT 96902180T AT E364701 T1 ATE364701 T1 AT E364701T1
Authority
AT
Austria
Prior art keywords
insulin
immunoreactive
diabetes mellitus
interact
dependent diabetes
Prior art date
Application number
AT96902180T
Other languages
English (en)
Inventor
Leonard Harrison
Margo Honeyman
George Rudy
Andrew Lew
Original Assignee
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN1239A external-priority patent/AUPN123995A0/en
Priority claimed from AUPN5172A external-priority patent/AUPN517295A0/en
Application filed by Inst Medical W & E Hall filed Critical Inst Medical W & E Hall
Application granted granted Critical
Publication of ATE364701T1 publication Critical patent/ATE364701T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/81Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT96902180T 1995-02-20 1996-02-20 Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren ATE364701T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN1239A AUPN123995A0 (en) 1995-02-20 1995-02-20 Immunointeractive molecules
AUPN5172A AUPN517295A0 (en) 1995-09-04 1995-09-04 Immunointeractive and immunotherapeutic molecules

Publications (1)

Publication Number Publication Date
ATE364701T1 true ATE364701T1 (de) 2007-07-15

Family

ID=25644867

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96902180T ATE364701T1 (de) 1995-02-20 1996-02-20 Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren

Country Status (8)

Country Link
US (2) US6818217B1 (de)
EP (2) EP0815136B1 (de)
JP (1) JP3778936B2 (de)
AT (1) ATE364701T1 (de)
CA (1) CA2213301C (de)
DE (1) DE69637130T2 (de)
ES (1) ES2289751T3 (de)
WO (1) WO1996026218A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525784A1 (de) * 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
US7361331B2 (en) 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US7422747B2 (en) 1997-10-07 2008-09-09 Loma Linda University Transgenic plant-based vaccines
US6777546B2 (en) 1997-10-07 2004-08-17 Loma Linda University Methods and substances for preventing and treating autoimmune disease
SE9704451D0 (sv) * 1997-11-28 1997-11-28 Diamyd Therapeutics Ab New method and compositions for the treatment of autoimmune diseases
US6982323B1 (en) 1997-12-23 2006-01-03 Alexion Pharmaceuticals, Inc. Chimeric proteins for diagnosis and treatment of diabetes
WO1999032136A1 (en) * 1997-12-23 1999-07-01 Alexion Pharmaceuticals, Inc. Chimeric proteins for the treatment of diabetes
AU750623B2 (en) * 1998-04-22 2002-07-25 Loma Linda University Methods and substances for preventing and treating autoimmune disease
CA2387652A1 (en) * 1999-10-22 2001-05-03 The Walter And Eliza Hall Institute Of Medical Research A method of prophylaxis and treatment
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
AU2003300681A1 (en) * 2002-10-02 2004-05-04 Diamyd Medical Ab Formulation of glutarmic acid decarboxylase (gad65) and serum albumin
US20050209138A1 (en) * 2004-03-19 2005-09-22 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
US20050250691A1 (en) * 2004-05-10 2005-11-10 Diamyd Therapeutics Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
MX2009011481A (es) * 2007-04-24 2010-02-01 Diamyd Therapeutics Ab Medicamentos y metodos para tratar enfermedad autoinmune y cancer.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569792A (en) * 1984-06-14 1986-02-11 Eli Lilly And Company Anti-diabetic compounds
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
DK0572478T3 (da) 1991-02-22 2006-01-16 Inst Medical W & E Hall HBGAD- og HIGAD-polypeptider og nukleinsyre og anvendelse heraf til diagnostik og behandling af GAD-autoantigen-associerede sygdomme
WO1992020811A2 (en) 1991-05-15 1992-11-26 Zymogenetics, Inc. Cloning and expression of human islet glutamic acid decarboxylase autoantigen
RU2036592C1 (ru) 1991-08-16 1995-06-09 Моисей Михайлович Лернер Устройство для распределения предметов на технологические потоки
NZ245170A (en) * 1991-11-26 1994-07-26 Lilly Co Eli Insulin and proinsulin analogues with arg at b31, b32 and ao and pharmaceutical compositions
EP0600372B1 (de) * 1992-12-02 1997-02-05 Hoechst Aktiengesellschaft Verfahren zur Gewinnung von Proinsulin mit korrekt verbundenen Cystinbrücken
DE69334246D1 (de) 1992-12-03 2008-12-24 Univ California Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome
US5547847A (en) 1993-09-07 1996-08-20 University Of Washington Diagnosis of insulin-dependent diabetes
US6509165B1 (en) * 1994-07-08 2003-01-21 Trustees Of Dartmouth College Detection methods for type I diabetes
CN1157621A (zh) 1994-07-08 1997-08-20 达特茅斯大学理事会 用于检测和治疗i型糖尿病的胰岛素原肽化合物

Also Published As

Publication number Publication date
HK1004949A1 (en) 1998-12-18
US20020142004A1 (en) 2002-10-03
EP0815136B1 (de) 2007-06-13
CA2213301A1 (en) 1996-08-29
US6818217B1 (en) 2004-11-16
WO1996026218A1 (en) 1996-08-29
DE69637130T2 (de) 2008-02-21
EP0815136A1 (de) 1998-01-07
EP0815136A4 (de) 2001-02-07
US7455984B2 (en) 2008-11-25
JPH11500719A (ja) 1999-01-19
EP1849870A1 (de) 2007-10-31
JP3778936B2 (ja) 2006-05-24
CA2213301C (en) 2010-01-26
ES2289751T3 (es) 2008-02-01
DE69637130D1 (de) 2007-07-26

Similar Documents

Publication Publication Date Title
ATE364701T1 (de) Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren
DK228190A (da) Rajgraespollenallergen
DE3886060D1 (de) Vorläuferprotein des APC-Polypeptids, dafür codierende DNA und diagnostische Verwendung der DNA und des Proteins.
DE69635740D1 (de) Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
DE69333673D1 (de) Epitope von Stress Proteinen
ATE281521T1 (de) Von filaggrin abgeleitete antigene und deren anwendung in der diagnose von rheumatischer polyarthritis
UA42040C2 (uk) Поліпептид, спосіб діагностики інсулінозалежного цукрового діабету (iddm), що розвинувся або що розвивається (варіанти), набір для діагностики iddm (варіанти), препарат для запобігання або лікування iddm, фармацевтична композиція для профілактики або лікування iddm
ATE122394T1 (de) Pankreatische isletzellen-antigene, erhalten durch molekulare klonierung.
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
DE69230614D1 (de) Protein-s polypeptide und deren verwendungen
AUPR775401A0 (en) Novel Epitopes and Uses Thereof
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
DE69533545D1 (de) Faltende proteine
MX9800191A (es) Peptidos novedosos derivados de proteina humana 60 producida por choque termico, para tratamiento de diabetes, composiciones, metodos y equipos.
DK222390A (da) Heparin-bindende proteiner, dna'er, der koder for saadanne proteiner, fremgangsmaade til fremstilling af proteinerne same farmaceutiske praeparater indeholdende disse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties